Publications and Posters - Affimed

All categories

Publications

Posters

All Cell Engagers

acimtamig (AFM13)

AFM11

AFM24

AFM26

AFM28

Innate Cell Engager

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

Leveraging Innate and Adaptive Immunity with AFM24 and Atezolizumab in Metastatic Gastric Cancer

Saavedra et al.
ESMO 2024

The Bispecific Innate Cell Engager AFM28 Induces Potent Anti-Tumor Activity Against AML in a Xenograft Mouse and in a Bone Marrow Niche in vitro Model

Tsoukala et al.
EHA 2024

Preliminary results from the Phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC)

Kim et al.
ASCO 2024

Identifying potential pharmacokinetic profile modifiers to inform optimization of bispecific antibodies using an enhanced FcRn high-performance liquid chromatography, FcRn-pH-HPLC

Tasser et al.
PEGS-EU

Redirecting NK cell cytotoxicity by CD16A-specific Innate Cell Engagers: A differentiated and innovative approach compared to CAR-NK cells

Ciulean et al.
SITC 2023

AFM13 enhances the anti-tumoractivity of AB-101 towards CD30+tumors, conferring tumorgrowth control in vivo

Pahl et al.
NK2023

Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method

Müller, Tasser et al.
mAbs, ePub ahead of print

link to publication

AFM24 in Combination With Autologous NK Cells (SNK01) in Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) Expressing Solid Tumors: Initial Results From the Phase 1 Dose Escalation Study

El-Khoueiry et al.
ASCO Breakthrough 2023

AFM13 enhances the anti-tumor activity of AB-101 towards CD30+ tumors, conferring tumor growth control in vivo

17-ICML
Pahl et al.

AFM13 in Patients with R/R Peripheral T cell Lymphoma (PTCL): A Post-hoc Subgroup Analysis From the REDIRECT Study

EHA 2023
Kim et al.

1
2
3
4
5
6
7
8